China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q3 2024 earnings summary

Executive summary

• Achieved revenue of ¥19.74 billion for the first nine months of 2024, up 6.08% year-over-year; net profit attributable to shareholders reached ¥2.96 billion, up 23.19% year-over-year.

• Core CHC (consumer health) business and prescription drug segments showed robust growth, with brand influence and product innovation driving performance.

• Strategic M&A activity included a proposed acquisition of a 28% stake in Tasly Pharmaceutical for ¥6.21 billion, aiming to make Tasly a subsidiary and enhance industry synergy.

• Integration of Kunming Pharmaceutical Group progressed, focusing on organizational restructuring and brand building.

Financial highlights

• Q3 revenue was ¥5.63 billion, up 3.16% compared to the same quarter last year; Q3 net profit attributable to shareholders was ¥561 million, up 6.85%.

• Operating cash flow for the first nine months was ¥3.20 billion, up 5.05% year-over-year.

• Basic and diluted EPS for the first nine months were both ¥2.32, up from ¥1.88 year-over-year.

• Gross margin and operating margin improved, with net profit margin rising due to higher sales and cost control.

Outlook and guidance

• Management expects continued growth through brand strengthening, product innovation, and strategic M&A.

• Focus remains on expanding the CHC and prescription drug portfolios, leveraging R&D and market opportunities.